Hardman & Co Research: Shield Therapeutics (STX): Good demand for Feraccru in Europe
(WorldNews Europe)

Hardman & Co Research: Good demand for Feraccruin Europe Shield Therapeutics (STX) is a commercial-stage company delivering specialty products that address patients` unmet medical needs, with an initial focus on treating iron deficiency (ID) with ferric maltol. Recent news that the FDA had approved this drug for a broad indication opened upa market in the US currently worth over $1bn p.a. - a US partnership deal is expected in 2020. A 2019 trading update showed STX`s performance...